The challenges and optimization of cell-based therapy for cardiovascular disease
- PMID: 35136722
- PMCID: PMC8802397
- DOI: 10.2478/jtim-2021-0017
The challenges and optimization of cell-based therapy for cardiovascular disease
Abstract
With the hope of achieving real cardiovascular repair, cell-based therapy raised as a promising strategy for the treatment of cardiovascular disease (CVD) in the past two decades. Various types of cells have been studied for their reparative potential for CVD in the ensuing years. Despite the exciting results from animal experiments, the outcome of clinical trials is unsatisfactory and the development of cell-based therapy for CVD has hit a plateau nowadays. Thus, it is important to summarize the obstacles we are facing in this field in order to explore possible solutions for optimizing cell-based therapy and achieving real clinical application.
Keywords: cardiovascular disease; cell survival; cell-based therapy; homing; lineage differentiation.
© 2021 Shiyue Xu et al., published by Sciendo.
Conflict of interest statement
None declared.
Similar articles
-
AAV-mediated gene therapy: Advancing cardiovascular disease treatment.Front Cardiovasc Med. 2022 Aug 19;9:952755. doi: 10.3389/fcvm.2022.952755. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36061546 Free PMC article. Review.
-
Challenges for heart disease stem cell therapy.Vasc Health Risk Manag. 2012;8:99-113. doi: 10.2147/VHRM.S25665. Epub 2012 Feb 17. Vasc Health Risk Manag. 2012. PMID: 22399855 Free PMC article. Review.
-
Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data.PLoS Med. 2018 Mar 20;15(3):e1002538. doi: 10.1371/journal.pmed.1002538. eCollection 2018 Mar. PLoS Med. 2018. PMID: 29558462 Free PMC article.
-
Review of stem cell-based therapy for the treatment of cardiovascular disease.J Cardiovasc Transl Res. 2008 Jun;1(2):106-14. doi: 10.1007/s12265-008-9020-6. Epub 2008 Apr 22. J Cardiovasc Transl Res. 2008. PMID: 20559904 Review.
-
Stem cells and cardiac repair: a critical analysis.J Cardiovasc Transl Res. 2008 Mar;1(1):41-54. doi: 10.1007/s12265-007-9008-7. Epub 2008 Jan 31. J Cardiovasc Transl Res. 2008. PMID: 20559957 Review.
Cited by
-
Research Progress on N6-adenosylate Methylation RNA Modification in Heart Failure Remodeling.J Transl Int Med. 2023 Jan 5;10(4):340-348. doi: 10.2478/jtim-2022-0025. eCollection 2022 Dec. J Transl Int Med. 2023. PMID: 36860637 Free PMC article.
-
Stem cell- derived extracellular vesicles as new tools in regenerative medicine - Immunomodulatory role and future perspectives.Front Immunol. 2023 Jan 24;14:1120175. doi: 10.3389/fimmu.2023.1120175. eCollection 2023. Front Immunol. 2023. PMID: 36761725 Free PMC article. Review.
-
Can Extracellular Vesicles as Drug Delivery Systems Be a Game Changer in Cardiac Disease?Pharm Res. 2023 Apr;40(4):889-908. doi: 10.1007/s11095-022-03463-z. Epub 2022 Dec 28. Pharm Res. 2023. PMID: 36577860 Free PMC article. Review.
-
Emerging Strategies in Mesenchymal Stem Cell-Based Cardiovascular Therapeutics.Cells. 2024 May 17;13(10):855. doi: 10.3390/cells13100855. Cells. 2024. PMID: 38786076 Free PMC article. Review.
-
Exosomes-mediated drug delivery for the treatment of myocardial injury.Ann Med Surg (Lond). 2023 Dec 2;86(1):292-299. doi: 10.1097/MS9.0000000000001473. eCollection 2024 Jan. Ann Med Surg (Lond). 2023. PMID: 38222684 Free PMC article. Review.
References
-
- Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095–128. - PMC - PubMed
- Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128. - PMC - PubMed
-
- Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol 2017; 70: 1–25. - PMC - PubMed
- Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G. et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017;70:1–25. - PMC - PubMed
-
- Afzal MR, Samanta A, Shah ZI, Jeevanantham V, Abdel-Latif A, Zuba-Surma EK, et al. Use of contact force sensing technology during radiofrequency ablation reduces recurrence of atrial fibrillation: A systematic review and meta-analysis. Circ Res 2015; 117: 558–75. - PubMed
- Afzal MR, Samanta A, Shah ZI, Jeevanantham V, Abdel-Latif A, Zuba-Surma EK. et al. Use of contact force sensing technology during radiofrequency ablation reduces recurrence of atrial fibrillation: A systematic review and meta-analysis. Circ Res. 2015;117:558–75. - PubMed
-
- Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A 2000; 97: 3422–7. - PMC - PubMed
- Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M. et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A. 2000;97:3422–7. - PMC - PubMed
-
- Wollert KC, Meyer GP, Muller-Ehmsen J, Tschope C, Bonarjee V, Larsen AI, et al. Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial. Eur Heart J 2017; 38: 2936–43. - PubMed
- Wollert KC, Meyer GP, Muller-Ehmsen J, Tschope C, Bonarjee V, Larsen AI. et al. Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial. Eur Heart J. 2017;38:2936–43. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous